- Types of Eczema
- Child Eczema
- Causes & Triggers
- Living with Eczema
- Eczema Products
- Get Involved
We asked, you answered. The verdict? People living with eczema want more information and more options. This past January, many of you responded to a 6-question online survey to evaluate patient satisfaction and the role of doctors in the treatment of the most serious form of eczema, atopic dermatitis (AD). We learned that the vast majority of […]
Vice President, Advocacy and Access. Tim will be responsible for development and implementation of key advocacy initiatives that will advance NEA’s mission to improve the quality of life for individuals with eczema through research, support, and education. Tim most recently served as President of Foretop, a consulting firm that provided advocacy and business planning services […]
June 9, 2016 – On Monday, June 6, 2016 the pharmaceutical companies Regeneron and Sanofi, reported positive results for the Phase 3 the clinical trial of the new biologic drug, dupilumab, when used in conjunction with a topical corticosteroid by adults to treat moderate-to-severe atopic dermatitis (AD).
November 17, 2016 – This year, more than 450 people joined NEA on two successful Itching for a Cure (IFAC) Walks in Chicago, IL and Los Angeles, CA. Together, we raised nearly $120,000 to improve the quality of life for individuals with eczema through research, support, and education.
Erase the stigma of eczema Our boys Dylan (4) and Dean (2) suffer from eczema. We constantly wonder if our sons will be bullied or teased about their skin, and worry about what that could do to their self esteem and confidence. Talking about Itching for a Cure and our walk team helps people understand […]
August 20, 2015 – The National Eczema Association’s Eczema: Tools for School is a kit designed to help parents and educators give children with eczema the best possible school experience.
August 17, 2015 – The National Eczema Association (NEA) is pleased to share news about a potential new topical non-steroidal treatment for mild-to-moderate eczema that you, the National Eczema Association community, helped make possible.
July 20, 2015 – Early nutrition and adiposity have been linked to atopic dermatitis (AD) development.
July 20, 2015 – Researchers at Yale School of Medicine have successfully treated patients with moderate to severe eczema using a rheumatoid arthritis drug.
July 13, 2015 – Anacor Pharmaceuticals Announces Positive Top-Line Results From Two Phase 3 Pivotal Studies of Crisaborole Topical Ointment, 2% in Patients With Mild-to-Moderate Atopic Dermatitis.